Loading
A phase 3 trial testing Opevesostat in prostate cancer, now recruiting.
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) is a phase 3 interventional study registered as NCT06136624, led by Merck Sharp & Dohme, and recruiting on the registry. Official title: A Phase 3 Randomised, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-003). Planned enrolment is 1310 participants (estimated). The study started in 2023-12-31 and primary completion is expected in 2028-08-02. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Opevesostat, Metastatic castration-resistant prostate cancer, Merck & Co. (MSD), Prostate cancer.
Shares Opevesostat, Metastatic castration-resistant prostate cancer, Merck & Co. (MSD), Prostate cancer.
Shares Opevesostat, Metastatic castration-resistant prostate cancer, Merck & Co. (MSD), Prostate cancer.
Shares Opevesostat, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/